These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 32946600)
1. Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis. Deneau MR; Mack C; Mogul D; Perito ER; Valentino PL; Amir AZ; DiGuglielmo M; Draijer LG; El-Matary W; Furuya KN; Gupta N; Hochberg JT; Horslen S; Jensen MK; Jonas MM; Kerkar N; Koot BGP; Laborda TJ; Lee CK; Loomes KM; Martinez M; Miethke A; Miloh T; Mohammad S; Ovchinsky N; Rao G; Ricciuto A; Sathya P; Schwarz KB; Shah U; Singh R; Vitola B; Zizzo A; Guthery SL Hepatology; 2021 Mar; 73(3):1061-1073. PubMed ID: 32946600 [TBL] [Abstract][Full Text] [Related]
2. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Lindor KD; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; Mooney J; Sargeant C; Braaten J; Bernard T; King D; Miceli E; Schmoll J; Hoskin T; Thapa P; Enders F Hepatology; 2009 Sep; 50(3):808-14. PubMed ID: 19585548 [TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: Predictors of Gamma Glutamyltransferase Normalization and Favorable Clinical Course. Deneau M; Perito E; Ricciuto A; Gupta N; Kamath BM; Palle S; Vitola B; Smolka V; Ferrari F; Amir AZ; Miloh T; Papadopoulou A; Mohan P; Mack C; Kolho KL; Iorio R; El-Matary W; Venkat V; Chan A; Saubermann L; Valentino PL; Shah U; Miethke A; Lin H; Jensen MK J Pediatr; 2019 Jun; 209():92-96.e1. PubMed ID: 30878206 [TBL] [Abstract][Full Text] [Related]
4. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Färkkilä M; Karvonen AL; Nurmi H; Nuutinen H; Taavitsainen M; Pikkarainen P; Kärkkäinen P Hepatology; 2004 Dec; 40(6):1379-86. PubMed ID: 15565569 [TBL] [Abstract][Full Text] [Related]
5. A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study. Rahimpour S; Nasiri-Toosi M; Khalili H; Ebrahimi-Daryani N; Nouri-Taromlou MK; Azizi Z J Gastrointestin Liver Dis; 2016 Dec; 25(4):457-464. PubMed ID: 27981301 [TBL] [Abstract][Full Text] [Related]
6. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Mitchell SA; Bansi DS; Hunt N; Von Bergmann K; Fleming KA; Chapman RW Gastroenterology; 2001 Oct; 121(4):900-7. PubMed ID: 11606503 [TBL] [Abstract][Full Text] [Related]
7. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Harnois DM; Angulo P; Jorgensen RA; Larusso NF; Lindor KD Am J Gastroenterol; 2001 May; 96(5):1558-62. PubMed ID: 11374699 [TBL] [Abstract][Full Text] [Related]
14. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response. van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717 [TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384 [TBL] [Abstract][Full Text] [Related]
16. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. Cullen SN; Rust C; Fleming K; Edwards C; Beuers U; Chapman RW J Hepatol; 2008 May; 48(5):792-800. PubMed ID: 18314215 [TBL] [Abstract][Full Text] [Related]
17. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Smith T; Befeler AS Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678 [TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2 Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751 [TBL] [Abstract][Full Text] [Related]
19. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Eaton JE; Silveira MG; Pardi DS; Sinakos E; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Lindor KD Am J Gastroenterol; 2011 Sep; 106(9):1638-45. PubMed ID: 21556038 [TBL] [Abstract][Full Text] [Related]